$TGTX News Article - TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI(TM) (ublituximab) in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
https://marketwirenews.com/news-releases/tg-t...14461.html